A vet biotech dedicated to pets well-being

Vetbiolix aims to develop innovative products for treatment and prevention of diseases affecting Pets.

As pharmaceutical and biotech companies research novel molecules and compounds for human medicine, tests in different species often reveal exciting possibilities for pets.  Vetbiolix has developed a unique approach focused on turning this potential into innovative prescription medicines and care products for pets. Because, surprisingly, veterinarians have few therapeutics and real preventive care products at their disposal that have been specifically developed and approved for pets.

Along with a virtual VetBiotech organization, Vetbiolix focus exclusively on clinical development of prescription medicines, diagnostic, nutraceuticals and care products for pets thanks to qualified external R&D partners in Europe & US.

Vetbiolix is passionate about giving veterinarians, and their clients, science-driven therapeutic & preventive options

Pipeline

vetbiolix, prescription medicines, oncology, periodontal diseases, inflammation, animal health, veterinary treatment

PRESCRIPTION MEDICINES

3 products in Oncology,
Periodontal diseases
& Inflammation

vetbiolix, nutraceuticals, care products, ophtalmology, alopecia, dermatology, animal health, veterinary treatment

NUTRACEUTICALS
& CARE PRODUCTS

3 products in Ophthalmology,
Alopecia
& Dermatology

vetbiolix, diagnostic product, oncology, animal health, veterinary treatment

DIAGNOSTIC PRODUCTS

2 products in Oncology

Want to participate in our investment opportunities ?

Press Release

Vetbiolix renforce son pipeline avec le produit SOLUDOTSPaclitaxel pour le marché de l’oncologie vétérinaire au travers d’un accord de licence signé avec CARLINA Technologies

 

Lille, 08 Juillet 2020

Vetbiolix, une société de biotechnologie vétérinaire basée en France, a
annoncé aujourd’hui avoir conclu un accord de licence et de recherche exclusif et mondial avec CARLINA Technologies, une société de biotechnologie et de services basée en France spécialisée dans le développement de nanomédicaments, pour mener la phase de développement clinique de SOLUDOTS-Paclitaxel dans le traitement du cancer chez les animaux de compagnie.

Vetbiolix strengthens its pipeline with the SOLUDOTS-Paclitaxel product licensed from CARLINA Technologies for the veterinary oncology market

 

Lille, 08th July 2020

Vetbiolix, a French-based veterinary biotech company announced today
having entered into a worldwide, exclusive license and research agreement with CARLINA Technologies, a French-based contract service-based biotechnology company specialized in the development of nanomedicines to enter clinical development phase of SOLUDOTS-Paclitaxel for the
treatment of cancer in companion animals.

Contact us

Parc Eurasanté – Bio Incubateur
70, rue du Dr. Yersin
59120, Loos – France

+33 (0)6 88 19 30 93

image
https://www.vetbiolix.com/wp-content/themes/imperio/
https://www.vetbiolix.com/
#68CDE4
style1
paged
Loading posts...
/home/vetbiolipk/www/
#
on
none
loading
#
Sort Gallery
on
yes
yes
off
Enter your email here
on
on